Skip to main content
spacbrain

Vesicor Therapeutics

Closed (deSPAC)

Health Care · microvesicle-based cancer therapeutics development

What it is
A private company in health care preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now
Merging with Altitude Acquisition Corp. (ALTU) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.
Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

What the company says about itself

Web research — not audited

Vesicor Therapeutics, Inc. is a company focused on transforming oncology through precision-engineered microvesicles that deliver p53 mRNA directly to cancer cells using a non-viral, immune-silent delivery platform.

Markets:
Oncology | Gene Therapy
Products:
ecm-RV/p53 | Precision-engineered microvesicle architecture
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics to Go Public via $70M SPAC Merger" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal Size, $M $70.00M" [https://www.spacresearch.com/symbol/BKHAU] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Vesicor at $70 million pre-money" [https://dealforma.com/cancer-rd-partnerships-ma-and-ventures-h1-2025-review/] [WEB-INTEL 2026-08-27] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics to Go Public via $70M SPAC Merger" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal Size, $M $70.00M" [https://www.spacresearch.com/symbol/BKHAU] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Vesicor at $70 million pre-money" [https://dealforma.com/cancer-rd-partnerships-ma-and-ventures-h1-2025-review/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Latest Deal Amount $70M" [https://pitchbook.com/profiles/company/589840-12] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Reverse Merger 26-Apr-2025 $70M Announced" [https://pitchbook.com/profiles/company/589840-12] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-27] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-27] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-27] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-27] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics to Go Public via $70M SPAC Merger... with completion expected in Q4" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal Size, $M $70.00M" [https://www.spacresearch.com/symbol/BKHAU] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7" [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html] [WEB-INTEL 2026-08-27] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics to Go Public via $70M SPAC Merger" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal Size, $M $70.00M" [https://www.spacresearch.com/symbol/BKHAU] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Vesicor at $70 million pre-money" [https://dealforma.com/cancer-rd-partnerships-ma-and-ventures-h1-2025-review/] [WEB-INTEL 2026-08-27] 4 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal Size, $M $70.00M" [https://www.spacresearch.com/symbol/BKHAU] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics to Go Public via $70M SPAC Merger" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Vesicor at $70 million pre-money" [https://dealforma.com/cancer-rd-partnerships-ma-and-ventures-h1-2025-review/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor Therapeutics has announced plans to merge with Black Hawk Acquisition Corp. in a $70 million SPAC deal" [https://trial.medpath.com/news/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy] [WEB-INTEL 2026-08-27] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) [WEB-INTEL 2026-08-27] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vesicor was founded in 2008 by Luo Feng, Ph.D." [https://www.latimes.com/b2b/health-life-science/story/2025-05-09/vesicor-therapeutics-black-hawk-spac-merger] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Vesicor at $70 million pre-money" [https://dealforma.com/cancer-rd-partnerships-ma-and-ventures-h1-2025-review/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Altitude Acquisition announced a business combination agreement with Vesicor Therapeutics at a $70 million valuation. Filing June 14, 2024." [https://news.spacconference.com/2024/03/01/altitude-acquisition-merging-with-vesicor-therapeutics-in-70m-deal/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Vescior hopes to raise between $10 million and $13 million from the offering" [https://labusinessjournal.com/healthcare/biotech-firm-gets-a-new-leader/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shareholders redeemed 4,775,923 public shares for about $51.0 million, leaving 2,124,077 public shares outstanding and approximately $22.7 ..." [https://www.stocktitan.net/sec-filings/BKHA/10-q-black-hawk-acquisition-corp-quarterly-earnings-report-3a50394c893a.html]

Source: https://vesicor.com/ · captured Aug 27, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Vesicor Therapeutics is merging with Altitude Acquisition Corp. (ALTU) currently marked Closed (deSPAC).

Headline equity value$70M

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Was this deal done at an expensive or a cheap valuation?

SpacBrain’s read on the price

No multiple can be computed

We hold no revenue figure in US dollars for Vesicor Therapeutics, Inc., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $70M regardless.

We have not extracted a revenue figure for this company from its filings yet. That is our gap, not a statement about the business.

What the buyers are paying for the whole company$70M

Announced equity value (net debt unknown).

Divided by what the company actually sells in a yearno revenue figure on file

Not extracted from the filings yet.

= what this deal pays for every dollar of those salesno multiple

Not computable — no revenue figure has been extracted from the filings yet.

What the stock market pays for its closest listed peersno comparable multiple

No listed comparable carries a revenue multiple we can use.

What qualifies the figures above

  • The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.

Common questions

Is Vesicor Therapeutics going public?

Vesicor Therapeutics has an approved merger with the SPAC Altitude Acquisition Corp. (ALTU). Deal status: Closed (deSPAC).

What is Vesicor Therapeutics's SPAC deal valuation?

The announced headline equity value is $70M.

Was Vesicor Therapeutics bought at an expensive or a cheap valuation?

We hold no revenue figure in US dollars for Vesicor Therapeutics, Inc., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $70M regardless.

Does Vesicor Therapeutics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals